Litcius/Paper detail

Non‐coding RNAs to treat vascular smooth muscle cell dysfunction

Simon Brown, Eftychia Klimi, Wilfried A.M. Bakker, Abdelaziz Beqqali, Andrew H. Baker

2024British Journal of Pharmacology14 citationsDOIOpen Access PDF

Abstract

Vascular smooth muscle cell (vSMC) dysfunction is a critical contributor to cardiovascular diseases, including atherosclerosis, restenosis and vein graft failure. Recent advances have unveiled a fascinating range of non-coding RNAs (ncRNAs) that play a pivotal role in regulating vSMC function. This review aims to provide an in-depth analysis of the mechanisms underlying vSMC dysfunction and the therapeutic potential of various ncRNAs in mitigating this dysfunction, either preventing or reversing it. We explore the intricate interplay of microRNAs, long-non-coding RNAs and circular RNAs, shedding light on their roles in regulating key signalling pathways associated with vSMC dysfunction. We also discuss the prospects and challenges associated with developing ncRNA-based therapies for this prevalent type of cardiovascular pathology. LINKED ARTICLES: This article is part of a themed issue Non-coding RNA Therapeutics. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v182.2/issuetoc.

Topics & Concepts

microRNAVascular smooth muscleNon-coding RNABiologyLong non-coding RNABioinformaticsEndothelial dysfunctionCell functionRestenosisCellSmooth muscleMedicineNeuroscienceRNAInternal medicineEndocrinologyGeneGeneticsStentCancer-related molecular mechanisms researchCircular RNAs in diseasesMicroRNA in disease regulation
Non‐coding RNAs to treat vascular smooth muscle cell dysfunction | Litcius